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The structure and function of the equine herpesvirus type 1 (EHV-1) UL34 homologous protein were characterized. A UL34
protein-specific antiserum reacted with an Mr28,000 protein that could not be detected in purified extracellular virions.
Confocal laser scanning microscopy demonstrated that UL34 reactivity mainly concentrated at the nuclear rim, which
changed into a punctuate and filamentous pattern at late times after infection. These changes in UL34 distribution were
especially prominent when analyzing the distribution of a GFP-UL34 fusion protein. A UL34-negative EHV-1 was generated
by mutagenesis of a recently established BAC clone of EHV-1 strain RacH (pRacH). Release of extracellular infectious virus
was severely impaired after infection of Rk13 cells with H34. Electron microscopy revealed a virtual absence of virus
particles in the cytoplasm of infected cells, whereas nucleocapsid formation and maturation within the nucleus appeared
unaffected. A UL34-GFP fusion protein with GFP linked to the C-terminus of UL34 was able to complement for the UL34
deletion in trans, while a GFP-UL34-fusion protein with GFP linked to the N-terminus of UL34 was able to only partially restore
virus growth. It was concluded that the EHV-1 UL34 product is essential for an early step in virus egress, i.e., release ofINTRODUCTION
Infection of horses with equine herpesvirus type 1
(EHV-1) gives rise to symptoms ranging from respiratory
to neurological disorder or fetal death (Allen and Bryans,
1986). The sequence of the complete EHV-1 genome, a
member of the Alphaherpesvirinae, has been deter-
mined, demonstrating a coding capacity for at least 76
proteins (Telford et al., 1992). To date, only some of these
proteins have been associated with a function in the
EHV-1 replication cycle (Osterrieder et al., 1996, 1998;
Sun et al., 1996; Neubauer et al., 1997; Garko-Buczinsky
et al., 1998; Purewal et al., 1998; Meindl and Osterrieder,
1999; Osterrieder, 1999; Csellner et al., 2000; Oettler et
al., 2001). Nevertheless, several EHV-1 products, e.g.,
glycoproteins B (gB), gD, gM, or the products of the
UL45-homologous gene 15, gene 71, or gene 68 (the IR6
product), are known to play a role in virus egress or
cell-to-cell spread (Osterrieder et al., 1996, 1998; Sun et
al., 1996; Neubauer et al., 1997; Csellner et al., 2000;
Oettler et al., 2001, Rudolph and Osterrieder, 2002).
The egress of other Alphaherpesvirinae has recently
been studied intensively, resulting in a better under-
1 To whom correspondence and reprint requests should be ad-standing of the general process. For most Alphaherpes-
virinae it is now accepted that particles undergo two
distinct steps of tegumentation and envelopment. A tem-
porary envelope is acquired by budding at the inner
nuclear membrane, which is followed by the secondary
and final addition of tegument and envelope by budding
into Golgi vesicles. The two viral envelopes differ in
appearance and protein content (Gershon et al., 1994;
Whiteley et al., 1999; Klupp et al., 2000; Granzow et al.,
2001, Roizman and Knipe, 2001; Cohen and Strauss, 2001,
Mettenleiter, 2002).
Various proteins are involved in Alphaherpesvirus
egress, some of which seem to be dispensable, while
others are essential for virus replication in vitro. The
complex multistep process of herpesvirus egress is an
only partially understood interplay between tegument
and envelope proteins, which involves a large number of
viral proteins, many of which have not yet been assigned
to a specific function (Mettenleiter, 2002).
HSV-1 UL34 belongs to a group of proteins which are
phosphorylated by the viral protein kinase US3 (Purves
et al., 1991). US3 is nonessential for replication in vitro,
but the protein kinase does have an influence on the
virulence of HSV-2 on the distribution of the UL34 protein
in infected cells and on virus egress of PrV (Nishiyama etcapsids from infected-cell nuclei. © 2002 Elsevier Science (USA
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UL34 proteins of HSV-1 or PrV are necessary for an early
step in virus egress; the protein is involved in acquiring
the primary envelope at the inner nuclear membrane and
is thus important for nuclear egress (Roller et al., 2000;
Klupp et al., 2000). The HSV-1 UL34 protein was found to
be virion-associated after copurification of intracellular
and extracellular particles (Purves et al., 1992). The PrV
homolog was not detected in extracellular virions, but
was present in envelopes of early intracellular particles
(Klupp et al., 2000). In addition the HSV-1 UL34 has been
shown to bind to dynein side chains and is thought to be
connected with the intracellular, dynein-mediated trans-
port of capsids occurring right after virus entry (Sodeik et
al., 1997; Ye et al., 2000a). The HSV-1 UL34 protein is
membrane-associated and proposed to have a type II
transmembrane protein topology (Purves et al., 1992;
Roller et al., 2000), which is assumed for most UL34
homologous proteins (Klupp et al., 2000; Shiba et al.,
2000) and is in accordance with an influence on virus
maturation. Another interesting feature is the interaction
of the UL34 and UL31 proteins. The UL31 protein physi-
cally interacts with the UL34 protein and is dependent on
the expression of UL34 for its stability and localization at
the nuclear rim (Ye et al., 2000a,b; Reynolds et al., 2001).
The presented study aimed at an analysis of the EHV-1
UL34 homolog to advance the understanding of EHV-1
egress. The UL34 open reading frames are well con-
served throughout the Herpesviridae, although only few
homologs have been analyzed to date and functional
roles attributed to them are still contradictory (Purves et
al., 1992; Ye et al., 2000a,b; Reynolds et al., 2001; Klupp et
al., 2000; Shiba et al.,. 2000). Therefore, the EHV-1 UL34
homologous protein was identified and its structure and
intracellular localization was analyzed. Further, its role in
the EHV-1 life cycle in vitro was determined. It is shown
that the EHV-1 UL34 protein accumulates at the nuclear
rim and that it is involved in nucleocapsid egress from
infected-cell nuclei. The N-terminal cytoplasmic domain
of the type II transmembrane protein appears to be
important for function, as demonstrated by analyzing the
function of two different GFP-UL34 fusion proteins.
RESULTS
Detection of the EHV-1 UL34 homologous protein
An anti-UL34 antiserum (-UL34) was raised in rabbits
against a UL34-GST fusion protein (Fig. 1C), encompass-
ing amino acids 1 to 246 of the 275 amino acid EHV-1
UL34 polypeptide. The UL34 protein-specific antiserum
was used for Western blot analyses of lysates of RacH-
or RacL22-infected Rk13 cells. The antiserum specifically
bound to an Mr 28,000 polypeptide in cells infected with
either RacL22 or RacH. In time course experiments, the
UL34-specific band was detected from 6 h postinfection
(p.i.) and its intensity increased until a maximum level
was reached at 9 h p.i. (Fig. 2A, UL34). This pattern of
UL34 reactivity corresponded nicely to the expression of
other early-late EHV-1 proteins as is exemplaril shown
for EHV-1 gB (Fig. 2A, gB). The assignment of UL34
expression to the early-late class of protein expression
was confirmed by experiments using phosphono acetic
acid (PAA), which inhibits de novo viral DNA synthesis.
As shown in Fig. 2B, the expression of UL34 (gene 26)
was clearly reduced in the presence of 0.5 to 1.0 mg of
PAA per ml of cell culture medium, while expression of
the early IR6-protein was not affected. In contrast, ex-
pression of UL45 (gene 15), a true late protein, was
precluded by addition of PAA to infected cells (Fig. 2B).
The EHV-1 UL34 product is not glycosylated and is a
type II transmembrane protein that is not detectable
in extracellular virions
Predictions of the secondary structure of the UL34
polypeptide (GCG software package; Fig. 3A) indicated a
putative transmembrane anchor at the C-terminus of the
protein and an N-glycosylation consensus sequence,
which could theoretically be used if the protein was a
type I transmembrane protein and entered the lumen of
the endoplasmic reticulum (ER). In deglycosylation ex-
periments using N-glycosidase F on RacL22-infected
Rk13 cells at 14 h p.i., no shift in electrophoretic mobility
of the UL34 protein was observed, indicating that the
protein was not N-glycosylated. In a parallel deglycosy-
lation experiment, the expected alterations in electro-
phoretic mobility of the gB was demonstrated using the
same lysates and buffer systems (Fig. 3B).
Using coupled in vitro transcription-translation of UL34
with recombinant expression plasmid pC26 (Fig. 1) as a
template, no alteration in the relative Mr of the products
was observed whether translation was performed in the
absence or presence of microsomal membranes (Fig.
3C, Lanes 1, 2). In addition, no protection of the in vitro
translated product to digestion with proteinase K was
observed in the presence of microsomal membranes
(Fig. 3C, Lanes 3 to 6), again indicating that the major
part of the protein did not enter the lumen of micro-
somes.
As has been shown for the PrV-homolog (Klupp et al.,
2000), the EHV-1 UL34 product could not be detected in
virions purified from supernatants of RacH- or RacL22-
infected cells. In preparations of purified extracellular
RacH or RacL22 virions, no UL34-specific reactivity was
observed, whereas on a parallel blot on identical prep-
arations, a strong signal of the processed form of gB was
present, demonstrating the purity of the virion prepara-
tions (Fig. 4). From the results of the deglycosylation and
proteinase K protection experiments, as well as from the
analysis of purified extracellular virions, it was con-
cluded that the EHV-1 UL34 product represents a type II
transmembrane protein that is not incorporated into ex-
tracellular EHV-1 virions.
190 NEUBAUER ET AL.
Subcellular localization of the EHV-1 UL34 protein
Rk13 cells that had been infected for 14 h with RacL22
were separated into fractions containing nuclear, mem-
brane-associated proteins or proteins of the soluble frac-
tion of the cytoplasm. Western blot analysis of fractions
demonstrated that the EHV-1 UL34 (gene 26) product,
although not a type I transmembrane protein (see above
and Fig. 3), was membrane associated, because the
UL34-specific antibody detected theMr 28,000 UL34 pro-
tein-specific band, especially in the nuclear and the
membrane-associated fraction (data not shown). Al-
though UL34 expression was relatively more prominent
in the nuclear than in the membrane-associated fraction,
this pattern still reflected the intracellular distribution of
other viral transmembrane proteins. To take a closer look
at the distribution of UL34 reactivity in infected cells,
Rk13 cells were infected with RacL22 and fixed with
acetone at different time points after infection (Fig. 5A).
Nuclei were stained with propidium iodide, while the
UL34 protein was visualized using the -UL34 antibody.
UL34 protein-specific reactivity was concentrated at the
nuclear rim, but was also found within the cytoplasm and
appeared to change at later times after infection. Addi-
tionally, a more punctuate UL34 protein pattern and other
structures resembling folds within and at the nuclear
membranes were observed from 10 h p.i. with increasing
intensities (Fig. 5A).
In further experiments addressing the distribution of
the EHV-1 UL34 protein, recombinant plasmids p26NGFP
and pGFPC26 (Fig. 1C) were used to generate Rk13-
based cell lines, that either express a fusion protein, with
GFP linked to the C-terminus of UL34 (26NGFP), or a
fusion protein with GFP linked to the N-terminus of the
UL34 protein (GFPC26). Both cell lines were similar in
their fluorescence pattern, and a marked nuclear rim
fluorescence was observed. However, the UL34-GFP fu-
sion proteins were also detected in the cytoplasm (Fig.
5B). The distribution of the fluorescence changed mark-
edly when the recombinant cell lines were infected with
EHV-1 strain RacL22. Fluorescence of superinfected
cells changed from the originally observed, dominant
nuclear rim staining, to fluorescing dots on—or filaments
around—infected-cell nuclei. These fluorescent patches
were observed throughout the cytoplasm at later times
FIG. 1. Map of the virus and plasmid constructs used in this study. (A) The BamHI map of EHV-1 strain RacH-based pRacH is shown and an
additional BamHI site within sequences of the inserted mini F plasmid pHA2 (black box) is marked by a plus (A). Features and construction of pRacH
have been explained elsewhere (Rudolph and Osterrieder, 2002). The location of the EHV-1 genes 25, 26, and 27 representing open reading frames
homologous to UL33 to UL35 is depicted within the set of AvrII-HindIII fragment (B). The construction of plasmids pGXAE (B), pC26, p26NGFP,
pGFPC26, and pGEX26 (C) as well as the PCR product conferring kanamycin resistance (kan), used for the generation of H34 (B), is described under
Materials and Methods. TM, potential transmembrane domain of UL34; N, putative N-glycosylation site. Restriction enzyme recognition sites are
indicated.
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p.i., irrespective of the fusion protein analyzed (Fig. 5B). It
must be noted, however, that the punctuate pattern,
which was predominant at later time points after infec-
tion, was also rarely observed in single uninfected cells.
At present, we are unable to allocate this fluorescent
pattern to any subcellular compartment but we view an
accumulation of the UL34 protein in certain areas of the
ER as likely.
Construction of UL34 negative EHV-1 strain RacH
The structural data presented in the first part of this
study mainly focused on analysis of the EHV-1 wild-type
strain RacL22, while the functional data were generated
using the RacH strain. To study the function of the EHV-1
UL34 product, 70% of gene 26 (UL34) sequences was
deleted of the RacH genome, which has been cloned as
a bacterial artificial chromosome (BAC) and termed
pRacH (Rudolph and Osterrieder, 2002). By recE/T-medi-
ated recombination of a PCR-generated linear fragment
into pRacH using DH10B cells, a kanamycin resistance
(kan) gene was introduced, thereby replacing nucleo-
tides 1 to 578 of the EHV-1 UL34 ORF (gene 26) (Fig. 1B)
(Schumacher et al., 2000; Rudolph and Osterrieder,
2002). pRacH carries sequences of the mini F plasmid
pHA2 (Adler et al., 2000), including a HCMV immediate
early promoter/enhancer-driven GFP-expression-cas-
sette replacing EHV-1 gene 71 (gp2; Fig. 1A). DNA of the
mutated pRacH conferring kanamycin resistance to
DH10B cells, named pRacH34 (Fig. 1), was analyzed by
agarose gel electrophoresis and Southern blotting and
used to transfect Rk13 cells or cell lines 26NGFP and
GFPC26 (Fig. 5B). Only single GFP-positive cells or small
foci of infected cells were observed after transfection of
pRacH34 into Rk13 cells or cell line GFPC26, while the
virus reconstituted from the mutated BAC clone termed
H34 replicated well on cell line 26NGFP and was fur-
ther propagated on this cell line. The deletion of UL34
was restored by cotransfection of Rk13 cells with
pRacH34 DNA and plasmid pGXAE containing an AvrII-
HindIII fragment which contains UL34 (gene 26) and
adjacent sequences (Fig. 1B). The resulting UL34 rever-
tant virus termed H34R was isolated after three rounds
of plaque purification and propagated on Rk13 cells.
Finally, BAC vector sequences in pRacH34 were re-
placed with authentic gene 71 sequences by recombina-
tion with plasmid p71 (Rudolph and Osterrieder, 2002).
The resulting virus progeny, termed H34Rgp2, was also
purified to homogeneity, selecting for GFP-negative
plaques on UL34-complementing cells. After the second
passage in cell culture, viral DNA of Hgp2 (Rudolph and
Osterrieder, 2002), H34, H34R, and H34Rgp2 was
prepared, and the genotypes were analyzed by Southern
blotting using a kan and the viral AvrII-HindIII fragment of
plasmid pGXAE (Fig. 1B) as specific probes. These
probes were used to confirm correct recombination,
while a digoxigenin-labeled pRacH-DNA was applied to
exclude undesired changes in the restriction enzyme
pattern of the virus mutants. The results of the Southern
blot experiments are summarized in Fig. 6. As expected,
the labeled AvrII-HindIII fragment hybridized to the
BamHI-a (20.4 kb) and the HindIII-a fragment (20.6 kb) of
Hgp2 DNA or H34R DNA. Replacing 578 bp of UL34
sequences by the 970 bp kan gene resulted in an addi-
tion of 392 bp, including one HindIII site. Therefore, the
AvrII-HindIII probe hybridized to a 20.8 kb (BamHI) or to
16.2 and 4.8 kb fragments on HindIII-cleaved DNA of
H34. Corresponding H34 fragments reacted with the
kan probe, while no kan sequences were detectable in
DNA of Hgp2 and H34R. Comparing DNA banding
patterns after incubation with labeled pRacH as a probe,
it was noted that the resulting fragments corresponded
to calculated fragment sizes: The addition of pHA2 se-
FIG. 2. Western blot analysis of Rk13 cells that were infected at an
m.o.i. of 3 with RacL22. Cells were either lysed at the given times after
infection (A) or lysed after a 14-h incubation in the presence of PAA in
the concentrations indicated (B). Lysates were subjected to 12% PAGE
and blots were incubated with an anti-IR6 (O’Callaghan et al., 1994), or
an anti-UL45 rabbit antiserum (Oettler et al., 2001), the anti-gB MAK 3F6
(Allen and Yeargan, 1987), or the anti-UL34 antibody. Prestained mo-
lecular weight marker sizes (Biolabs) are indicated in thousands.
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quences into RacH resulted in another BamHI site (see
also Fig. 1A), and two new fragments in DNA containing
pHA2 sequences emerged (Fig. 6, asterisks), while the
original BamHI-d fragment (10.5 kb) disappeared. Since
these sequences were repaired to paternal RacH se-
quences in H34Rgp2, the BamHI-d fragment (10.5 kb)
was restored (Fig. 6). Finally, the insertion of pHA2 re-
sulted in a new HindIII fragment of 17.4 kb (8.7 and 1.1 kb,
plus addition of 7.6 kb due to the insertion) (Fig. 6,
asterisks). Taken together, the banding pattern of
the viral DNA exactly corresponded to what had been
calculated for either insertion of pHA2 or deletion of
UL34 sequences. No additional mutations or changes
were observed. The restoration of gp2 expression in
H34Rgp2 was additionally analyzed using anti-gp2-
Mab 3B12 (Meyer and Hu¨bert, 1988; Rudolph and Oster-
rieder, 2002; data not shown).
The EHV-1 UL34 protein is essential for virus growth
In a first step, Rk13 or 26NGFP cells were infected with
Hgp2, H34, or H34R and lysed at 14 h p.i. to compare
expression of UL34 and of other early-late proteins by
Western blot analysis. As shown in Fig. 7, no UL34-
specific reactivity was found in Rk13 cells infected with
the UL34-negative RacH virus mutant. In addition it was
demonstrated that deletion of UL34 did not influence the
production of early-late proteins, such as gB or gM. The
UL34-GFP fusion protein expressed by cell line 26NGFP
was reactive with the UL34-specific antibodies and ex-
hibited an apparent Mr of 60,000 as would have been
predicted (Fig. 7).
Plaque diameters after infection of Rk13, 26NGFP, or
GFPC26 cells with Hgp2, H34, or H34R were deter-
FIG. 3. Analysis of membrane orientation of the EHV-1 UL34 protein. (A) The putative membrane anchor and N-glycosylation consensus site are
indicated in a Kyte–Doolittle hydrophilicity blot (GCG software package) according to the amino acid sequence of the EHV-1 UL34 product. (B) Western
blot analysis of RacL22-infected Rk13 cells lysed in N-glycosidase F buffer at 14 h p.i. and incubated for 16 h at 37°C with (0.4 U) or without (buf.)
addition of N-glycosidase F. Blots were probed with the anti-UL34 antibody or with anti-gB Mab 3F6. (C) SDS–PAGE analysis (12%) of in vitro
transcribed and translated UL34 products. Plasmid pC26 was used as a template and the reactions were performed in the absence (Lane 1) or
presence of microsomal membranes (Lanes 2–6). To some reactions, proteinase K was added (ProtK, Lanes 3–6), to some PMSF (Lanes 4, 6), and/or
Triton X-100 (Triton, Lanes 5,6). Sizes of a prestained molecular weight marker (Biolabs) are indicated in thousands.
FIG. 4. Western blot analysis of RacH and RacL22 virions purified
from supernatants of infected cells, and of lysates of RacH and RacL22
infected Rk13 cells (14h p.i.). Parallel blots were incubated with the
anti-UL34 antibody or anti-gB Mab 3F6. Sizes of a prestained molecular
weight marker (Biolabs) are indicated in thousands.
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FIG. 5. (A) Rk13 cells were infected with EHV-1 strain RacL22 and acetone-fixed at the times p.i. indicated. The UL34 protein was detected using
the anti-UL34 antiserum followed by an anti-rabbit Alexa488 secondary antibody (Molecular Probes, green). Nuclei were visualized using propidium
iodide (PI, red). Arrowheads emphasize changes in the fluorescence pattern late in infection. (B) 26NGFP and GFPC26 cells, grown on glass
coverslips, were directly analyzed after fixation with paraformaldehyde. In the third panel, typical changes in the fluorescence pattern of cell line
26NGFP after infection with RacL22 (m.o.i.: 0.1; 14 h p.i.) are shown. Cells were analyzed by confocal laser scanning microscopy (Magnification,630).
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mined, and examples of resulting plaques are shown in
Fig. 8. It could be clearly demonstrated that the UL34
negative virus was able to infect single Rk13 cells only,
while infection with the parental or the rescuant virus
resulted in the appearance of plaques exhibiting wild-
type morphology. Plaque formation of H34 was restored
on cell line 26NGFP, but infection of cells expressing
GFP fused to the amino-terminus of UL34 (GFPC26)
resulted in very small plaques only (Fig. 8). The fluores-
cence pattern of wild-type GFP expressed by recombi-
nant viruses was different from that observed in cells
expressing the UL34-GFP fusion protein. In addition, all
virus mutants tested replicated with slightly reduced lev-
els on cell line 26NGFP. Using this cell line, virus plaques
also appeared smaller (Fig. 8). Infection of Rk13 or
26NGFP cells with H34Rgp2, the virus in which gp2
expression was restored but which still was not able to
express the UL34 protein, resulted in plaques which
were very similar in phenotype to those observed after
infection with H34 virus (data not shown).
Virus growth properties of the various mutant viruses
were compared on Rk13 and 26NGFP cells. Cells seeded
in six-well plates were infected at an multiplicity of in-
fection (m.o.i.) of 2 and extracellular (ec) and intracellular
(ic) virus titers were determined at different time points
p.i. (Fig. 9). While growth properties of the rescuant
H34R virus corresponded well to those of Hgp2 on
either cell line (Figs. 9A and 9B), there was a marked
inhibition in the production of H34 extracellular virus
titers on Rk13 cells. Within this series of experiments
(mean of three independent experiments), at no time
point after infection could any extracellular infectivity be
FIG. 7. Western blot analysis of Rk13 or 26NGFP cells infected with
Hgp2, H34, or H34R at an m.o.i. of 3. Blots were incubated with the
anti-UL34 antibody, anti gB Mab 3F6, or anti gM Mab B2. Molecular
weight marker sizes are indicated in thousands.
FIG. 6. Southern blot analysis of Hgp2, H34Rgp2, H34, and of
H34R. DNA was cleaved with BamHI or HindIII, separated by 0.8%
agarose gel electrophoresis, blotted onto nylon membranes, and incu-
bated with a kanamycin-specific probe (kan), the digoxigenin-labeled
EHV-1 AvrII-HindIII fragment (Fig. 1B), or with labeled pRacH DNA
(pRacH). DNA hybrids were detected by chemiluminescence using
CSPD. Marker sizes (1-kb ladder; Biolabs) are given in kb on the
margins. The arrowheads point to DNA fragments affected by the
deletion of UL34, while the asterisks highlight fragments carrying
sequences of the BAC vector pHA2 (Rudolph and Osterrieder, 2002).
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detected. Even at 24 h p.i. no extracellular infectivity was
observed, although cells were dying and detached from
the solid support. Low titers of intracellular infectivity,
however, were found and peaked at 9 h p.i. (1.1  103
PFU, Fig. 9A). Using recombinant cell line 26NGFP, the
growth defect of H34 was virtually completely rescued
(Fig. 9B). These results proved that the observed growth
defect was caused by the deletion of UL34 and that the
GFP-fusion protein expressed by this cell line can effi-
ciently complement the observed growth defect of the
H34 mutant in trans. Rudolph and Osterrieder (2002)
analyzed the effect of the deletion of gp2 on the growth
properties of Hgp2 and showed that the mutant virus
was not significantly impaired in virus growth, virus
egress, or cell-to-cell spread. To analyze the possibility
of an influence of an absence of gp2 on the phenotype
observed for the H34 mutant, further growth kinetics
were performed which compared growth of Hgp2,
H34, and the virus expressing gp2 but not the UL34
protein (H34Rgp2; Fig. 9C). It could be demonstrated
that intracellular titers of H34gp2 and the double-mu-
tant virus H34 were low and that growth properties of
both UL34 negative viruses were severely reduced.
While extracellular infectivity after infection of Rk13 cells
with H34 (5  101 PFU) was detected only in one of six
experiments, infection with H34gp2 resulted in extra-
cellular titers (maximum at 9.0  103 PFU) after 24 h of
infection (in three of three experiments). It was therefore
concluded that virus growth after deletion of UL34 in
Hgp2 was further reduced by the additional deletion of
gp2. Growth properties on 26NGFP cells were again very
similar for all three viruses (data not shown). Finally, Rk13
and 26NGFP cells were infected with Hgp2 and H34
at an m.o.i. of 2. At 14 h p.i., supernatants were harvested
and virus titers were determined (Table 1), while cells
were fixed and embedded for electron microscopical
analyses. In Rk13 cells infected with Hgp2, all stages of
particle formation could be identified, ranging from dif-
ferent types of capsids inside of the nucleus to maturing
particles in the cytoplasm. Large numbers of mature
particles in the extracellular space were also observed
(Fig. 10A). No difference to the picture of an EHV-1 strain
RacH infection was obvious. In contrast, mostly intranu-
clear capsids were observed in Rk13 cells infected with
H34 (Fig. 10B). Extremely rarely were herpesvirus par-
ticles detected in the cytoplasm or in secretory vesicles.
Finally, sections of cell line 26NGFP were analyzed. As a
general observation, lower numbers of virus particles
were observed, although exactly the same m.o.i. and
incubation time had been used as for Rk13 cells (also
Table 1). When 26NGFP cells were infected with either
Hgp2 or H34, however, no difference between the two
FIG. 8. Cell lines 26NGFP and GFPC26 or Rk13 cells in six-well plates were infected with 50 PFU of Hgp2, H34, or H34R, respectively, as
indicated. The sizes of infected foci were analyzed in an Axiovert (Magnification, 100; Zeiss) at Day 3 p.i. by GFP-fluorescence of infected cells.
Pictures were scanned and digitally processed.
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viruses was evident. As stated above, lower numbers of
particles could be identified, but these particles were
observed undergoing all stages of maturation (results
are exemplarity shown for H34; Figs. 10C–10E). H34
particles budding at the nuclear membranes (Fig. 10D)
and next to a Golgi stack (Fig. 10E) are pointed out to
emphasize different stages of maturation, which were
observed on the complementing cell line 26NGFP. These
data suggested that the deletion of the UL34 homolo-
gous gene 26 of EHV-1 led to a defect in virus replication
which prevents virus maturation to progress beyond the
formation of DNA-containing capsids and thus has a
severe impact on a step in early virus egress, i.e., egress
of newly synthesized EHV-1 capsids from infected-cell
nuclei.
DISCUSSION
In this communication it was shown that the UL34
homolog of Equine Herpesvirus 1 is an early-late protein,
which is not detectable in extracellular virions. Other
main findings were that the EHV-1 UL34 protein is a type
II transmembrane protein which localizes predominantly
at the nuclear rim of infected and transfected cells and
that the pattern of UL34 fluorescence changes during the
course of infection. Through functional analysis of a
UL34-negative virus, it was demonstrated that the EHV-1
UL34 homolog is essential for virus egress in cell culture
and that its deletion causes a block in virus replication
before primary envelopment occurs at the inner nuclear
membrane. Finally, the deletion of UL34 can be comple-
mented for in trans by a cell line expressing a GFP-UL34
fusion protein when GFP is fused to the C- but not the
N-terminus of UL34.
The EHV-1 UL34 protein was determined by Western
blotting to be expressed as an Mr 28,000 polypeptide.
This size corresponded well to the calculated Mr of
30,679. Predictions on the deduced EHV-1 UL34 protein
structure indicated a putative membrane anchor and a
putative N-glycosylation site. Amino acid sequence iden-
tity between the EHV-1 protein and the UL34 products of
HSV-1 and PrV ranges from 45 to 51%, but the putative
membrane anchor is—in contrast to the N-glycosylation
TABLE 1
Titers in supernatants of infected RK13 and 26NGFP cells
Rk13 26NGFP
Cell line
for
titration: Hgp2 H34 Hgp2 H34
Rk13 0.7 105 No plaques 0.3 104 No plaques
26NGFP 0.7 105 101 0.65 104 0.85 105
FIG. 9. Rk13 (A, C) or 26NGFP (B) cells were infected at an m.o.i. of 2 of the indicated viruses. Kinetics of virus growth are depicted as virus titers
determined in supernatants of infected cells (closed symbols: Hgp2-ec (A–C), H34-ec (A–C), H34R-ec (A, B) or H34Rgp2-ec (C)) or in infected
cells (open symbols: Hgp2-ic (A–C), H34-ic (A–C), H34R-ic (A, B), or H34Rgp2-ic (C)). Shown are means of three individual and independent
experiments, respectively. Standard deviations are given above symbols as error bars.
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FIG. 10. Electron micrographs of Rk13 cells infected with Hgp2 (A) or with H34 (B) (both 14 h p.i.). Some capsids are indicated by arrowheads
within the nucleus, while particles present in the cytoplasm were only observed in cells infected with Hgp2 (arrows). (C–E) 26NGFP-cells infected
with H34 are shown. All stages of egress are readily observed (E). Particles budding at nuclear membranes (C) and particles within the proximity
of a Golgi stack (D) are emphasized. Bars represent 1.5 m (A, B), 250 nm (C, D), and 750 nm (E), respectively. N, Nucleus; G, Golgi network; CP,
cytoplasm.
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consensus sequence which is absent from the HSV-1
polypeptide—a conserved feature. A cleavable N-termi-
nal signal sequence is very unlikely, although this had
been previously assumed for HSV-1 (Purves et al., 1992).
The fact that the N-glycosylation consensus sequence
was not used for addition of sugar side chains in the
FIG. 10—Continued
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EHV-1 UL34 protein, neither in the in vitro translated
product nor in the viral protein, and that no protection
against proteinase K digestion was observed in the pres-
ence of microsomal membranes strongly suggested that
EHV-1 UL34 does not exhibit a type I topology in mem-
branes. Fractionation of infected cells and immunofluo-
rescence studies, however, clearly demonstrated a
membrane association of the protein. Taking structural
predictions and our experimental data into account, the
UL34 protein is very likely to constitute a tail-anchored
type II membrane protein. This is supported by the fact
that the addition of GFP to the C-terminus, i.e., directly
following the putative transmembrane domain of the
UL34 protein, influenced neither protein localization
within cells nor the ability to functionally complement the
defect of a UL34-negative EHV-1. In contrast, addition of
GFP to the N-terminus of UL34 did not have an obvious
effect on subcellular protein distribution but on function-
ality. We presently speculate that GFP could either influ-
ence protein folding by N-terminal fusion to the UL34
ORF during protein synthesis or—even more likely—
influence UL34 function by masking the region important
for the putative interactions of UL34 with other viral or
cellular proteins, e.g., with the product of the UL31 ho-
mologous gene (Reynolds et al., 2001). It was noted that
all viruses replicated with slightly reduced kinetics on
complementing cell line 26NGFP, as reflected by virus
titers, plaque sizes, and particle numbers observed in
electron microscopy of infected 26NGFP cells. This ef-
fect appears not to be caused by insufficient comple-
mentation for UL34, because it was independent from
UL34 expression. It has therefore to be considered that
either cells less susceptible to EHV-1 replication had
been selected while isolating 26NGFP cell clones or that
the 26NGFP protein itself has a transdominant negative
effect on virus growth. The latter could then either be
caused by the presence of GFP at the C-terminus of
UL34, resulting in a slight but dominant negative effect
on virus replication, or—because 26NGFP cells consti-
tutively express the UL34-GFP fusion protein—by the
preexistence of large amounts of UL34. It is interesting
that the fluorescence patterns of both UL34-GFP fusion
proteins changed during the course of infection, corrob-
orating the theory that the reduced function of the
GFPC26 fusion protein cannot primarily be explained by
protein misfolding or missorting. The influence of infec-
tion on the localization of UL34 appears to be stronger in
the case of 26NGFP cells when compared to Rk13 cells.
One possible explanation could be that preexisting UL34
protein accelerates an effect that usually occurs very late
in infection. As mentioned before, we were not able to
identify a specific subcellular compartment, which could
correspond to the observed fluorescence patterns, but a
presence of the UL34 in the ER is very likely. The ob-
served changes in UL34 protein distribution might thus
either reflect unspecific, general changes in cellular
structures at later times after infection or changes that
are a consequence of the role of the UL34 protein in virus
replication. Ongoing experiments are addressing these
questions. Analysis of an UL34 deletion mutant allowed
us to pinpoint the function of the protein on virus release.
Virtually no extracellular infectivity was detected after
infection of Rk13 cells with H34 and intracellular infec-
tivity was severely reduced. Electron microscopical anal-
yses enabled us to identify the action of the UL34 protein
during a step relatively early in virus maturation. Capsid
egress from infected-cell nuclei is apparently precluded,
because all forms of viral nucleocapsids were found
within the nucleoplasm of infected cells, but no nucleo-
capsids budding at the inner nuclear membrane were
observed, and virtually no virus particles in the cyto-
plasm of infected cells could be identified. However, the
replication status of the cell—as has been shown for the
gK deletion in HSV-1 (Jayachandra et al., 1997)—might
represent the key in interpreting the observation that low
levels of infectious virus were produced. The mutation
within the nonessential gene 71 of EHV-1 has been
thoroughly analyzed by Rudolph and Osterrieder (2002)
and deletion of gp2 in RacH was shown to cause no
significant reduction in intracellular virus titers. Virus
egress and cell-to-cell spread were only slightly re-
duced. To analyze the effect of the gp2 deletion on the
UL34 deletion mutant, additional experiments were un-
dertaken to compare H34 to the UL34-negative but
gp2-restored virus. Because virus replication of this mu-
tant was similarly blocked and because growth of all
UL34-negative virus mutants could be completely re-
stored on UL34 complementing cells, conclusive evi-
dence was provided that the UL34 protein is by itself
important for virus release from infected-cell nuclei. The
slight reduction in virus egress, that has been reported
earlier to be caused by the deletion of gp2 (Rudolph and
Osterrieder, 2002), might now additionally hinder from
egress those few particles which can leave the nucleus
in the absence of the UL34 protein. This might explain
the difference in extracellular virus titers that were ob-
served for the UL34 deletion mutants in the presence or
absence of gp2.
MATERIALS AND METHODS
Plasmids
To express a UL34-GST fusion protein, a portion of the
UL34-ORF (bp 4 to 738) was amplified by PCR and
inserted into vector pGEX4T-1 (Amersham Bioscience)
using primers containing an EcoRI and SalI recognition
site, respectively (pGEX26; Fig. 1C). Plasmids p26NGFP
and pGFPC26 (Fig. 1C) were constructed for expression
of UL34-GFP fusion proteins by PCR amplification of
UL34 sequences (827 bp, stop codon excluded) of EHV-1
strain RacL22 using the PFU-polymerase (Stratagene).
Restriction endonucleases EcoRI and KpnI (sites were
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included within PCR primer sequences) were used to
insert the amplification product into vector pEGFP-N1 or
pEGFP-C1 (Clontech). Correct amplification of all PCR
products was confirmed by cycle sequencing (MWG Bio-
tech). The HCMV promoter-driven plasmid pC26 arose
by removing the UL34 insert of p26NGFP, using EcoRI
and KpnI, and ligating the fragment into the EcoRI and
SphI sites of vector pcDNAI/Amp (Invitrogen), after blunt-
end adjustment of the SphI and KpnI sites. Trimming the
20,429-bp BamHI- a fragment of EHV-1, using HindIII and
AvrII to the 6427-bp fragment depicted in Fig. 1B resulted
in plasmid pGXAE (in vector pTZ18R, Pharmacia)
Cells and viruses
Equine dermal cell line Edmin337 and rabbit kidney
cell line Rk13 were maintained in minimal essential
medium supplemented with 5–10% fetal calf serum
(Neubauer et al., 1997). Recombinant cell lines 26NGFP
and GFPC26 were generated by Effectene (Qiagen)-me-
diated transfection of 1 g plasmid p26NGFP or pG-
FPC26, respectively, into Rk13 cells. Cell clones were
first selected for G418 (Calbiochem) resistance, then for
GFP-fluorescence and maintained in cell culture medium
supplemented with 500 g/ml of G418. Wild-type EHV-1
strain RacL22, and its attenuated cell culture derivative
RacH (Hu¨bert et al., 1996), as well as Hgp2, the virus
reconstituted from the RacH BAC pRacH (Rudolph and
Osterrieder, 2002), and its recombinant derivatives were
propagated on the respective cell lines.
Generation of recombinant viruses
Recombinant virus H34 was generated by E/T clon-
ing of EHV-1 BAC DNA in Escherichia coli, exactly as
described before (Schumacher et al., 2000; Rudolph and
Osterrieder, 2002). Briefly, plasmid pGETrec (kindly pro-
vided by Dr. Panos Ioannou, Murdoch Institute, Mel-
bourne, Australia) carrying the recE, recT, and bacterio-
phage  gam genes, to catalyze homologous recombi-
nation between linear DNA fragments and circular DNA,
was transformed into DH10B cells that contained pRacH.
Electrocompetent cells were prepared as described be-
fore (Schumacher et al., 2000; Rudolph and Osterrieder,
2002) and electroporated using a PCR fragment, carrying
the kan gene of plasmid pACYC177 (MBI Fermentas)
flanked by recombination arms. Primers were selected
such that the recombination arms of 50 nt enabled the
deletion of bp 1 to 578 of the EHV-1 UL34 gene (Primer:
1: 5agtcgcttaagggggttgactggccgctgttgggacatttcgctacaa-
cgccagtgttacaaccaattaacc3, 2: 5gatgctccctgggggaga-
ctataccgttactgcgatcgcacgagtctacgcgatttattcaacaaagcc-
acg3; primer sequences necessary for amplification of
the kan gene are in bold letters). Colonies harboring
mutated pRacH were selected for by resistance to kana-
mycin. DNA was prepared (Schumacher et al., 2000;
Rudolph and Osterrieder, 2002) and analyzed by restric-
tion fragment pattern analysis after separation on aga-
rose gels and also by Southern blot, before being trans-
fected into Rk13 cells or complementing cell lines (see
Results).
The UL34-repaired virus H34R was isolated after
cotransfection of plasmid pGXAE with DNA of pRacH34
into Rk13 cells, followed by three rounds of plaque puri-
fication. The gene 71 restored, but still UL34-negative
virus, H34Rgp2 was generated by reintroducing the
RacH gene 71 sequences into the genome of H34,
thereby deleting all sequences of the mini F plasmid
pHA2 (plasmid p71, Rudolph and Osterrieder, 2002).
Southern blot analysis
Viral DNA was prepared from Rk13 cells and from
complementing cell line 26NGFP infected with the re-
spective viruses (Osterrieder et al., 1996), or of DH10B
cells harboring DNA of pRacH or pRacH34 (Rudolph
and Osterrieder, 2002). DNA was cleaved with restriction
endonucleases; the resulting fragments were separated
by 0.8% agarose gel electrophoresis and blotted onto
positively charged nylon membranes, as previously de-
scribed (Osterrieder et al., 1996; Neubauer et al., 1997).
The kan gene, the viral AvrII-HindIII fragment of plasmid
pGXAE (Fig. 1B), and gene 71 sequences of plasmid p71
(Rudolph and Osterrieder, 2002), respectively, were used
as specific probes, while digoxigenin-labeled DNA of
pRacH was used to exclude any unspecific changes in
the restriction enzyme pattern. Digoxigenin 11–dUTP-
labeled DNA hybrids were detected using an antidigoxi-
genin alkaline phosphatase conjugate (Roche Molecular
Biochemicals) and visualized using CSPD for chemilumi-
nescence detection according to the manufacturer’s
(Roche Molecular Biochemicals) instructions.
Purification of virions
Rk13 cells were infected at an m.o.i. of 3 to 5; super-
natants were harvested at 14 h p.i. and cleared of cell
detritus by low-speed centrifugation. Virions were puri-
fied by repeated centrifugation through a 30% sucrose
cushion, as has been described elsewhere (Oettler et al.,
2001). The purity and integrity of virion preparations was
examined by electron microscopy.
Antibodies
The monoclonal anti EHV-1-gB antibody 3F6 (Allen and
Yeargan, 1987), anti EHV-1 UL45 polyclonal rabbit anti-
body (Oettler et al., 2001), anti EHV-1-gM monoclonal
antibody (Day, 1999), the anti-EHV-1-IR6 polyclonal rabbit
antiserum (O’Callaghan et al., 1994), and anti-gp2 anti-
body 3B12 (Meyer and Hu¨bert, 1988) were used in this
study. To generate UL34-specific antibodies, a UL34-GST
fusion protein (Fig. 1C) was expressed in E. coli strain
M15 and purified by sodium dodecyl sulfate (SDS)–poly-
acrylamide gel electrophoresis (PAGE) using an Electro-
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Eluter (Millipore). The quantity and quality of the purified
protein was confirmed by PAGE and subsequent Coo-
massie brilliant blue staining and by Western blot anal-
ysis using the GST-B14 monoclonal antibody (Santa Cruz
Laboratories). The polyclonal anti-UL34 serum was gen-
erated in rabbits immunized four times in 4-week inter-
vals with 50–100 g of the purified protein.
Western blotting and indirect immunofluorescence
Rk13, Edmin337, or 26NGFP-cells were infected with
the indicated viruses (m.o.i. of 3) and cell lysates were
prepared at the stated time points p.i. Samples were
adjusted to 1 mg/ml protein (BCA protein assay; Pierce)
and mixed with buffer containing 5% 2-mercaptoethanol
(Sambrook et al., 1989). The samples were then either
heated to 95°C for 5 min or to 56°C for 2 min (gM), and
proteins were then separated by SDS–12% PAGE. West-
ern blotting was done exactly as described before
(Oettler et al., 2001). Antibody binding was visualized
using anti-mouse or anti-rabbit immunoglobulin G (IgG)
peroxidase conjugate (Sigma) followed by ECL detection
(Pharmacia-Amersham).
For indirect immunofluorescence analysis (IIF), cells
grown on glass slides were infected with RacL22 (m.o.i.
of 3) and fixed at 0, 3, 6, 8, 10, or 12 h p.i. with 80%
acetone. GFP-expressing cells were either directly visu-
alized or visualized after paraformaldehyde (2%) fixation.
Further processing was done as has been described
before (Oettler et al., 2001). Finally, the samples were
analyzed and digitally documented using either an Axio-
vert or an LSM510 laser scanning microscope (Zeiss,
Oberkochen, Germany).
Analysis of protein synthesis and deglycosylation
experiments
Inhibition of DNA synthesis was achieved by addition
of PAA at a concentration of 0.1, 0.5, or 1 mg per ml of cell
culture medium. Infected cells were lysed after an incu-
bation of 14 h and subjected to SDS–PAGE.
N-linked carbohydrates were removed using N-glyco-
sidase F (peptide-N-glycosidase F, Roche Molecular Bio-
chemicals). At 14 h p.i., cells were resuspended in N-
glycosidase F buffer (Osterrieder et al., 1997) and incu-
bated for 16 h in the presence or absence of 0.4 U
N-glycosidase F.
Coupled in vitro transcription-translation
Plasmid pC26 was used as a template in a TNT T7-
coupled reticulocyte lysate transcription-translation sys-
tem (Promega) according to the manufacturer’s instruc-
tions. To study initial translational processing of proteins,
canine pancreatic microsomal membranes (Promega)
were added to the reaction. Translated proteins were
subjected to a proteinase K protection assay. In this
experiment, the in vitro translated protein, obtained in the
presence of canine pancreatic microsomal membranes,
was separated into several aliquots. Aliquots were incu-
bated for 60 min on ice with 0.1 mg/ml proteinase K
(Roche Molecular Biochemicals); in some control reac-
tions 10 mM phenylmethylsulfonyl fluoride (PMSF) and/or
Triton X-100 (1%) were added. All reactions were then
immediately stopped by adding PMSF, mixed with sam-
ple buffer, and subjected immediately to SDS–PAGE (Mo
and Holland, 1997).
Fractionation of cells
Rk13 cells that had been infected with RacL22 (m.o.i.
of 5) for 14 h were separated into fractions, as described
by Bogner et al. (1992).
Virus growth kinetics and plaque size measurements
The various viruses were allowed to adsorb to Rk13 or
26NGFP cells in six-well plates for 2 h at 4°C. After 90
min of incubation at 37°C to allow virus penetration, all
extracellular virus was inactivated using a citrate buffer
(pH 3.0). At the indicated times, parallel samples of
supernatants and infected cell pellets were harvested.
Cells were again treated with citrate buffer to exclude
contamination with extracellular infectivity, while super-
natants were cleared of cellular debris by low-speed
centrifugation. Intracellular and extracellular virus titers
were compared at each time point by plaque titration on
24-well plates of Rk13 cells or of complementing cell line
26NGFP, respectively. Plaque sizes on Rk13, 26NGFP, or
GFPC26 cells were determined after infection of cells in
six-well plates with 50 PFU per well of the respective
viruses and incubation for 3 days under a 0.25% methyl-
cellulose overlay (Oettler et al., 2001). Plaques were
visualized in an Axiovert microscope (Zeiss); pictures
were taken, scanned, and digitally processed.
Electron microscopy
Rk13 or 26NFGFP cells in 75-cm2 cell-culture flasks
were infected at an m.o.i. of 3 with either Hgp2 or H34.
Cells were fixed at 14 h p.i. for 2 h in 5% glutaraldehyde,
4% formaldehyde, buffered with a 0.1 M Na-phosphate
buffer to pH 7.4, and then washed with 0.1 M Na-phos-
phate buffer. Cells were postfixed for 2 h with 1% OsO4,
0.8% K3Fe(CN)6 in 0.1 M Na-phosphate buffer. All speci-
mens were stained for 90 min with 2% aqueous uranyl
acetate, dehydrated in graded ethanol, and embedded in
ERL 4206 (Spurr, 1969). The blocks were sectioned on an
Ultracut microtome (Reichert-Jung, Nuloch, Germany),
stained with uranyl acetate and lead citrate (Plattner and
Zingsheim, 1987), and examined with a transmission
electron microscope EM 10C/CR (Zeiss) at 80 kV.
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